Skip to content

SI-BONE, Inc. SIBN Free cash flow margin

Free cash flow margin at other companies

Stryker logo
StrykerSYK
18.1%+2.7pp
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
17.3%-1.6pp
Globus Medical logo
Globus MedicalGMED
19.7%-1.1pp
Alphatec Holdings logo
Alphatec HoldingsATEC
-12.7%-5.1pp
Medtronic logo
MedtronicMDT
14.9%-0.5pp
IAR
Integra LifeSciencesIART
3.8%-6.3pp

Other financials

Income statement

See full
Revenue$52.6M+11.2%
Gross profit$41.9M+11.3%
Operating income-$5.1M+31.9%
Net income-$4.3M+33.8%
EPS (diluted)-$0.10+33.3%

Balance sheet

See full
Cash & equivalents$33.5M-18.6%
Total debt$42.9M+15.6%
Total equity$178.9M+7.0%
Total assets$242.7M+6.8%

Cash flow

See full
Operating cash flow-$2.4M+51.9%
CapEx$1.1M-48.0%
Free cash flow-$3.4M+50.8%

Valuation

See full
Market cap$743.29M+6.4%
Enterprise value$752.71M+8.4%
P/S3.6×-0.4×

Profitability

See full
Gross margin79.6%+0.3pp
Operating margin-9.7%-3.0pp
Net margin-8.1%-2.6pp

Returns & leverage

See full
Return on equity-9.6%-2.7pp
Debt / equity0.2×0.0×
Current ratio10×+1.5×

Where this comes from

Calculated from SI-BONE, Inc.’s reported figures.

Based on trailing twelve months.

The official record: SI-BONE, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about SI-BONE, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SI-BONE, Inc.'s free cash flow margin?
SI-BONE, Inc. (SIBN) reported free cash flow margin of -2.9% in Q1 2026.
How has SI-BONE, Inc.'s free cash flow margin changed year-over-year?
SI-BONE, Inc.'s free cash flow margin increased by 74.7% year-over-year, from -11.5% to -2.9%.
What is the long-term trend for SI-BONE, Inc.'s free cash flow margin?
Over 5 years (2020 to 2025), SI-BONE, Inc.'s free cash flow margin has grown at a -36.3% compound annual growth rate (CAGR), from -45.3% to -4.7%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.